Screening, Prevention and Socioeconomic Costs Associated with the Treatment of Colorectal Cancer

PharmacoEconomics

Volumn 21, Issue 17, 2003, Pages 1213-1238

  Redaelli, Alberto ^a   Cranor, Carole W ^b   Okano, Gary J ^c   Reese, Pat Ray ^c  

^a Pharmacia Corporation   (Italy)

^b Pharmaceutical Product Development   (United States)

^c Reese Associates Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BALSALAZIDE; BCG VACCINE; BEVACIZUMAB; CALCIUM; CANVAXIN; CAPECITABINE; CELECOXIB; CETUXIMAB; EDRECOLOMAB; EFLORNITHINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; MONOCLAONAL ANTIBODY 17 1A; OLTIPRAZ; ONCOPHAGE; ORNITHINE; OXALIPLATIN; RALTITREXED; ROFECOXIB; SULINDAC; SULINDAC SULFONE; TEGAFUR; THERATOPE; UNCLASSIFIED DRUG; URACIL; URSODEOXYCHOLIC ACID; VACCINE;

AWARENESS; BARIUM ENEMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; CONTRAST ENHANCEMENT; COST BENEFIT ANALYSIS; DRUG COST; DRUG MECHANISM; EARLY DIAGNOSIS; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; LUNG CANCER; OCCULT BLOOD TEST; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SIGMOIDOSCOPY; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HEALTH CARE COSTS; HUMANS; RISK FACTORS;

EID: 0347589391     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321170-00001     Document Type: Review

References (134)

1. Agency for Health Care Policy and Research. Colorectal cancer screening: technical review. Rockville (MD): Agency for Health Care Policy and Research; 1998. AHCPR Publication No. 98-0033, 1-154
2. WHO. Global cancer rates could increase by 50% to 15 million by 2020. Available from URL: http://www.who.int/mediacentre/releases/2003/pr27/en/print. html [Accessed 2003 Aug 7]
3. The American Cancer Society (ACS). Cancer facts & figures, 2002, 41-43. Available from URL: http://www.cancer.org [Accessed 2003 Aug 7]
4. Singh PN, Fraser GE. Dietary risk factors for colon cancer in a low-risk population. Am J Epidemiol 1998; 148: 761-74
5. Potter JD. Nutrition and colorectal cancer. Cancer Causes Control 1996; 7: 127-46
6. Cohen AM, Minsky BD, Schilsky RL. Cancers of the gastrointestinal tract: cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 1144-97
7. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642
8. Byers T, Levin B, Rothenberger DA, et al. Am Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer. CA Cancer J Clin 1997; 47: 154-60
9. Ransohoff DF, Lang CA. Clinical guidelines: Part II. Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med 1997; 126: 811-22
10. Hoff G, Sauar J, Hofstad B, et al. The Norwegian guidelines for surveillance after polypectomy: 10-year intervals. Scand J Gastroenterol 1996; 31: 834-6
11. Madden MV. South African Gastroenterology Society guidelines for colonoscopy in premalignant conditions and after resection of large-bowel cancer. S Afr Med J 1992; 81: 369-70
12. Winawer SJ, St John DJ, Bond JH, et al. Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. Bull World Health Organ 1995; 73: 7-10
13. Palitz AM, Selby JV, Grossman S, et al. The colon cancer prevention program (CoCaP): rationale, implementation, and preliminary results. HMO Pract 1997; 11: 5-12
14. Kaye JA, Shulman LN. Screening program for colorectal cancer: effect on stage distribution. HMO Pract 1992; 6: 13-5
15. Atkin WS. Flexible sigmoidoscopy as a mass screening tool. Eur J Gastroenterol Hepatol 1998; 10: 219-23
16. Leard LE, Savides TJ, Ganiats TG. Patient preferences for colorectal cancer screening. J Fam Pract 1997; 45: 211-8
17. Cromwell DM, Moore RD, Bresinger JD, et al. Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis. Gastroenterology 1998; 114: 893-901
18. Vernon SW. Adherence to colorectal cancer screening: a brief overview. Ann N Y Acad Sci 1995; 768: 292-5
19. DiPalma AM, Barnes SE, DiPalma JA. Patient participation in colon cancer screening programs. South Med J 1998; 91: 342-4
20. Goh HS, Wong J. The Singapore polyposis registry. Ann Acad Med Singapore 1992; 21: 290-3
21. The American Cancer Society 1996 Advisory Committee. Guidelines on diet, nutrition, and cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. Cancer J Clin 1996; 46: 325-41
22. Greenwald P, McDonald SS. Cancer prevention: the roles of diet and chemoprevention. Cancer Control 1997; 4: 118-27
23. Martinez ME, McPherson RS, Levin B, et al. A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps. Gastroenterology 1997; 113: 423-9
24. Platz EA, Giovannucci E, Rimm EB, et al. Dietary fiber and distal colorectal adenoma in men. Cancer Epidemiol Biomarkers Prev 1997; 6: 661-70
25. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 1999; 340: 169-76
26. National Cancer Institute PDQ clinical trial abstracts [online]. Available from URL: http://www.nci.nih.gov/ [Accessed 2003 Sep 1]
27. Haile RW, Witte JS, Longnecker MP, et al. A sigmoidoscopy-based case-control study of polyps: macronutrients, fiber and meat consumption. Int J Cancer 1997; 73: 497-502
28. Jacobs DR, Marquart L, Slavin J, et al. Whole grain intake and cancer: an expanded review and meta-analysis. Nutr Cancer 1998; 30: 85-96
29. Slattery M, Edwards SL, Anderson K, et al. Vitamin E and colon cancer: is there an association? Nutr Cancer 1998; 30: 201-6
30. Hofstad B, Almendingen K, Vatn M, et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion 1998; 59: 148-56
31. Advisory Committee on Cancer Coordination and Control. Prevention in the North Carolina Cancer control plan 1996-2001. USA: American Cancer Society, NC Department of Environment, Health, and Natural Resources; 1996: I-9-I-18
32. Schatzkin A, Kelloff G. Chemo- and dietary prevention of colorectal cancer. Eur J Cancer 1995; 31A (7-8): 1198-204
33. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 1994; 331: 141-7
34. Jacobson JS, Neugut AI, Murray T, et al. Cigarette smoking and other behavioral risk factors for recurrence of colorectal adenomatous polyps. Cancer Causes Control 1994; 5: 215-20
35. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999; 340: 101-7
36. Kelloff GJ, Hawk ET, Crowell JA, et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 1996; 10: 1471-84
37. DuBois RN, Smalley WE. Cyclooxygenase, NSAIDs, and colorectal cancer. Gastroenterol 1996; 31: 898-906
38. Weiss HA, Forman D. Aspirin, NSAIDs and protection from colorectal cancer: a review of the epidemiological evidence. Scand J Gastroenterol Suppl. 1996; 220: 137-41
39. Thun MJ. Aspirin and gastrointestinal cancer. Adv Exp Med Biol 1997; 400A: 395-402
40. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20
41. Adis R&D Insight. Auckland: Adis International Ltd, 1999
42. IMSworld R&D Focus. London: IMS Global Services, 1998
43. Pharmaprojects database. Surrey: PJB Publications Ltd, 1997
44. Martinez ME, McPherson RS, Levin B et al. Aspirin and other NSAIDs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995; 4: 703-7
45. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-7
46. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6
47. Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and NSAIDs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993; 307: 285-9
48. Greenberg ER, Baron JA, Freeman DHJ, et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993; 85: 912-6
49. Nugent KP. Colorectal cancer: surgical prophylaxis and chemoprevention. Ann R Coll Surg Engl 1995; 77: 372-6
50. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patient. Gastroenterol Clin North Am 1996; 25: 349-62
51. Duris I, Hruby D, Pekarkova B, et al. Calcium chemoprevention in colorectal cancer. Hepatogastroenterology 1996; 43: 152-4
52. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996; 5: 779-84
53. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-50
54. Mayer RJ. Tumors of the large and small intestine. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. New York: McGraw-Hill Inc, 1994: 1424-31
55. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin 2000; 50 (1): 7-33
56. Cohen AM, Michelassi F, Galandiuk S. Colorectal cancer surgical practice guidelines. CRC Practice Guideline Committee. Oncology 1997; 11: 1051-7
57. Cancer management manual BCCA, gastrointestinal group. Available from URL: http://www.bccancer.bc.ca/cmm/03-10.html [Accessed 2003 Sep 19]
58. NICE. Guidance on the use of laparoscopic surgey for colorectal cancer. Technology Appraisal Guidance n.17. London: NICE, 2000 Dec
59. MacDonald JS. Adjuvant therapy for colon cancer. CA Cancer J Clin 1997; 47: 243-56
60. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. Available from URL:http//www.asco.org [Accessed 2003 Sep 30]
61. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87: 417-26
62. Brown ML, Riley GF, Potosky AL. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999 Dec; 37 (12): 1249-59
63. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol 2002 Feb; 97 (2): 440-5
64. Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL, editors. Cancer prevention and control. New York: Marcel Dekker Inc, 1995: 69-81
65. Seifeldin R, Hantasch IJ. The economic burden associated with colon cancer in the USA. Clin Ther 1999; 21 (8): 1370-9
66. Eaddy M, Bramley T, Kozma C, et al. Cost of colorectal cancer in the South Carolina Medicaid (SCM) population. Abstract 1633 (cat. Health Service Research). ASCO International Conference; 2000 May 20-23; New Orleans (LA)
67. Donowitz M. Gastrointestinal disease costs USA at least US$42 billion/year in 2001. Marketletter 2001 May 24
68. Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of breast and lung cancer. MedCare 1991; 29: 40-9
69. Geddes M, Carli S, Ercolanelli M, et al. Colorectal, lung, and breast cancer care during the three years following the diagnosis: a population-based study. Tumori 1996; 82: 210-4
70. Audisio RA, Cazzaniga M, Robertson C, et al. Elective surgery for colerectal cancer in the aged: a clinical-economical evaluation. Br J Cancer 1997; 76: 382-4
71. Chemotherapy for colorectal cancer. Prospects for the future. Inpharma 1996; Suppl. 2: 7
72. Mushinski M. Variation in in-hospital charges for colorectal cancer treatment. Stat Bull Metrop Insur Co 1998; 79: 19-27
73. Etzioni R, Scott RD, Berry C, et al. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. Health Econ 2001; 10: 245-56
74. Brown ML, Riley GF, Potosky AL, et al. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999; 37: 1249-59
75. Khullar SK, DiSario JA. Colon cancer screening: sigmoidoscopy or colonoscopy. Gastrointest Endosc Clin N Am 1997; 7: 365-86
76. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the fecal occult blood test, Hemoccult. BMJ 1998; 317: 559-65
77. Heine JA, Rothenberger DA. Cost-effective management of colon and rectal cancer. World J Surg 1991; 15: 597-604
78. Nelson RL. Screening of average-risk individuals for colorectal cancer and postoperative evaluation of patients with colorectal cancer. Surg Clin North Am 1996; 76: 35-45
79. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995; 109: 1781-90
80. US Congress Office of Technology Assessment. The cost-effectiveness of colorectal cancer screening in average-risk adults. OTA-BP-H-146. Washington, DC: US Government Printing Office, 1995
81. Marshall JR, Fay D, Lance P. Potential costs of flexible sigmoidoscopy-based colorectal cancer screening. Gastroenterology 1996; 111: 1411-7
82. Norum J. Prevention of colorectal cancer: a cost effectiveness approach to a screening model employing sigmoidoscopy. Ann Oncol 1998; 9: 613-8
83. Geul KW, Bosman FT, van Blankenstein M, et al. Prevention of colorectal cancer: costs and effectiveness of sigmoidoscopy. Scand J Gastroenterol Suppl 1997; 223: 79-87
84. Weller D, Moss J, Hiller J, et al. Screening for colorectal cancer: what are the costs? Int J Technol Assess Health Care 1995; 11: 26-39
85. Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991; 115: 807-17
86. Virgo KS, Vernava AM, Longo WE, et al. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995; 273: 1837-41
87. Rex DK, Mark D, Clarke B, et al. Flexible sigmoidoscopy plus air-contrast barium enema versus colonoscopy for evaluation of symptomatic patients without evidence of bleeding. Gastrointest Endosc 1995; 42: 132-8
88. Frazier AI, Colditz GA, Fuchs CS, et al. Cost effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284 (15): 1954-61
89. Brown ML, Kessler LG. The use of gene tests to detect hereditary predisposition to cancer: economic considerations. J Natl Cancer Inst 1995; 87: 1131-6
90. Straus W, Schaffner P, Gold K, et al. Colorectal cancer screening: awareness, utilization, and barriers [abstract]. Value Health 2001; 4 (2): 91
91. Subramanian S, Klosterman M, Amonkar MM, et al. Compliance with CRC screening guidelines: a review. Prev Med. In press
92. Legislative update: Final practice expense rulemaking and 1999 Medicare conversion factor and fee schedule rules 1998. Available from URL: www.acg.gi.org/abtacg/ldi.html [Accessed 2003 Sep 1]
93. Brown R, Sorensen S, Burrel A, et al. Cost-effectiveness analysis of irinotecan + 5FU/FA alone as first-line therapy in advanced colorectal cancer in the UK [abstract]. Value Health 2001; 4 (2): 54
94. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-FU and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002; 86 (11): 1677-83
95. Levy-Piedbois C, Durand-Zalesky I, Juhel H, et al. Cost effectiveness of second line treatment with irinotecan or infusional 5FU in metastatic colorectal cancer. Ann Oncol 2000; 11: 157-61
96. Schmitt C, Blijham G, Jolain B, et al. Medical care consumption in a phase III trial comparing irinotecan with infusional 5FU in patients with metastatic colorectal cancer after 5FU failure. Anticancer Drugs 1999; 10: 617-23
97. Iveson TJ, Hickish T, Schmitt C, et al. Irinotecan in second line treatment of metastatic colorectal cancer: improved survival and cost effect compared with infusional 5FU. Eur J Cancer 1999; 35 (13): 1796-804
98. Neymark N, Adriaenssen I, Schmitt C. Cost-effectiveness analysis of irinotecan compared with best estimated infusional 5FU regimen in patients with advanced colorectal cancer [abstract 461]. ASCO Conference; 1998 May 16-19; Los Angeles (CA)
99. Simons WR, Grace EM, et al. The comparative economic value of raltritrexed and 5FU plus leucovorin. Eur J Cancer 2000; Suppl. 3: 25
100. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy: a comparison of raltitrexed and 5FU plus leucovorin. Pharmacoconomics 2000; 17 (4): 361-70
101. Groener MGH, van Ineveld BM, Byttebier G, et al. An economic evaluation of Tomudex (raltitrexed) and 5FU plus leucovorin in advanced colorectal cancer. Anticancer Drugs 1999; 10: 1283-8
102. Ollendorf D. Impact of uracil/tegafur plus oral calcium folinate on resource utilization. Oncology 1999; 13 (7 Suppl. 3): 42-3
103. Murad AM, de Andrade CA, Delfino C, et al. Pharmacoeconomic evaluation of tegafur-uracil (UFT) vs 5FU for the management of colorectal cancer in Brazil and Argentina. Clin Drug Invest 1997; 13 (2): 90-8
104. Ron IG, Lotan A, Inbar MJ, et al. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anticancer Drugs 1996; 7: 649-54
105. Cavallo MC, Gerzeli S, De Carli C, et al. The cost of treatment for advanced colorectal cancer: a retrospective comparison of five chemotherapy regimens used in a Northern Italy hospital. Pharmacoeconomics 2001; 3 (1): 49-59
106. Norum J, Vonen B, Olsen JA, et al. Adjuvant chemotherapy (5FU and leucovorin) in Dukes' B and C colorectal cancer: a cost-effectiveness analysis. Ann Oncol 1997; 8: 65-70
107. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors. Part one: model projections for cost based on charges. Cancer 1996; 78: 294-9
108. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994; 86: 424-30
109. Kuvshinoff B. Incremental cost-effectiveness of different chemotherapy regimens in patients with unresectable colorectal liver metastases. Pharmacoeconomics & Outcomes News 1998; 182: 8
110. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of non-resectable colorectal liver metastases. J Natl Cancer Inst 1997; 89 (11): 790-5
111. Sorensen S, Brown R, De Cock E, et al. An analysis of resource use in the treatment of advanced colorectal cancer in the UK [abstract]. Value Health 2001; 4 (2): 90
112. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996; 32A Suppl. 5: S13-7
113. Blijham G. Impact of second-line therapy with irinotecan on healthcare resource use in patients with metastatic colorectal cancer. Pharmacoeconomics & Outcomes News 1998; 148: 3-4
114. Durand-Zaleski I, Earlam S, Fordy C, et al. Cost effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer 1998; 83 (5): 882-8
115. Focan C, on behalf of Cancer Chronotherapy Group. Pharmacoeconomic comparative evaluation between combination chronotherapy or standard chemotherapy for colorectal cancer [abstract PP17]. Eur J Cancer 2000; 36 (Suppl. 3): 14. 2nd European Conference of the Economics of Cancer; 2000 Sep 3-5; Brussels
116. Focan C, on behalf of Cancer Chronotherapy Group. Pharmacoeconomic comparative evaluation between combination chronotherapy or standard chemotherapy for colorectal cancer [abstract PP17]. Eur J Cancer 2000; 36 (Suppl. 3): 14. 2nd European Conference of the Economics of Cancer; 2000 Sep 3-5; Brussels
117. Trippoli S, Vaiani M, Cattei F, et al. Irinotecan combined with fluorouracil vs fluoruracil alone in metastatic colorectal cancer: cost effectiveness analysis [abstract PP63]. Eur J Cancer 2000; 36 (Suppl 3): 14. 2nd European Conference of the Economics of Cancer; 2000 Sep 3-5; Brussels
118. Trippoli S, Vaiani M, Cattei F, et al. Irinotecan combined with fluorouracil vs fluoruracil alone in metastatic colorectal cancer: cost effectiveness analysis [abstract PP63]. Eur J Cancer 2000; 36 (Suppl 3): 14. 2nd European Conference of the Economics of Cancer; 2000 Sep 3-5; Brussels
119. Douillard JY, Cunningham D, Roth AD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355: 1041-7
120. Cavallo MC, Gerzeli S, De Carli C, et al. The cost of treatment for advanced colorectal cancer: a retrospective comparison of five chemotherapy regimens used in a Northern Italy hospital. Pharmacoeconomics-Italian Research Articles 2001; 3 (1): 49-59
121. Nicholls CJ, Cassidy J, Freemantle N, et al. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone. J Drug Assess 2001; 4 ( Pt 3): 255-64
122. Nicholls CJ, Cassidy J, Freemantle N, et al. Cost-effectiveness of combination chemotherapy oxaliplatin or inrinotecan plus 5-FU/FA compared with 5-FU/FA alone. J Drug Assessment 2001; 4 (Pt 4): 215-26
123. Giuliani G, Lucioni C, Mazzi S, et al. Economic evaluation of oral capecitabine vs intravenous 5-FU/FA (Mayo regimen) in the treatment of advanced colorectal cancer. Pharmacoeconomics - Italian Research Articles 2002; 4 (1): 31-8
124. Hart WM, Pronk L, Obina S, et al. Cost-effectiveness analysis of irinotecan plus 5-FU/FA compared with 5-FU/FA alone as first line treatment of advanced colorectal cancer [abstract 2262] 38th Annual Meeting ASCO; 2002 May 18-21; Orlando (FL)
125. National Institute for Clinical Excellence (NICE). Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Technology appraisal no. 33, March 2002. Available from URL: http://www.nice.org.uk [Accessed 2003 Sep 2]
126. Norum J, Balteskard L, Edna TH, et al. Raltritrexed or nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on QOL, patients' preferences and health economics. J Chemother 2002; 14 (3): 301-8
127. Postma MJ., van Hartskamp D., Jansman FG et al. Cost analysis of capecitabine vs 5-FU/LV for colorectal cancer in patients in the Netherlands [abstract PCN 10]. ISPOR European Conference; 2002 Nov 3-5; Rotterdam
128. van den Hout WB, van den Brink M, Stiggelbout AM, et al. Cost effectiveness analysis of colorectal cancer treatments. Eur J Cancer 2002; 38: 953-63
129. Vorobyov P, Sura M, Avxentieva M, et al. Economical evaluation of raltitrexed vs 5-FU/LV for treatment of advanced colorectal cancer [abstract PCN 6]. ISPOR European Conference; 2002 Nov 3-5; Rotterdam
130. Global cancer rates could increase by 50% to 15 million by 2020. Available from URL: http://who.int/mediacentre/releases/2003/pr27/en/print.html [Accessed 2003 Jul 4])
131. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31
132. Ries LAG, Wingo PA, Miller DS, et al. The annual report of the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. American Cancer Society. Cancer 2000 May 15; 88 (10): 2398-424
133. Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL, editiors. Cancer prevention and control. New York: Marcel Dekker, 1995: 69-81
134. Seifeldin R, Hantsch J. The economic burden associated with colon cancer in the United States. Clin Ther 1999; 21 (8): 1370-9